Opus Genetics (IRD) Change in Accured Expenses (2010 - 2026)

Opus Genetics (IRD) has 17 years of Change in Accured Expenses data on file, last reported at $432000.0 in Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 58.82% year-over-year to $432000.0 in Q1 2026; TTM through Mar 2026 was -$3.3 million, a 179.08% decrease from a year earlier, with the FY2025 full-year figure at -$3.5 million, down 161.59% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $432000.0, up from -$873000.0 in the prior quarter.
• Over the last five years, Change in Accured Expenses for IRD reached as high as $2.4 million in Q4 2024 and fell as low as -$1.9 million in Q2 2025.
• Historically, Change in Accured Expenses has averaged $157882.4 across 5 years, with a median of $1000.0 in 2022.
• Across the five-year window, Change in Accured Expenses surged 149700.0% in 2023 and plunged 1109.94% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at $461000.0 in 2022, then slumped by 125.16% to -$116000.0 in 2023, then soared by 2129.31% to $2.4 million in 2024, then sank by 137.09% to -$873000.0 in 2025, then soared by 149.48% to $432000.0 in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were $432000.0 in Q1 2026, -$873000.0 in Q4 2025, and -$946000.0 in Q3 2025.